Communiqués Exscientia plc

Actions

EXAI

US30223G1022

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 19/11/2024			Varia. 5j.	Varia. 1 janv.
4,840 ^USD	+3,20%		-.--%	-

20/11/24	Recursion Pharmaceuticals et Exscientia achèvent le regroupement de leurs activités	MT
20/11/24	Recursion annonce des changements de direction	CI

Communiqués

20/11/24	Exscientia : Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery Form 6 K	PU
13/11/24	Exscientia : Recursion and Exscientia Shareholders Approve the Proposed Combination Form 6 K	PU
08/11/24	Exscientia : Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive (Loss)/Income for the three and nine months ended September 30, 2024 and 2023 Form 6 K	PU
06/11/24	Exscientia : FIRST AMENDMENT TO TRANSACTION AGREEMENT Form 6 K	PU
17/10/24	Exscientia franchit des étapes importantes pour deux de ses programmes dans le cadre de sa collaboration avec Sanofi	BU
16/10/24	Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration	BU
10/10/24	Exscientia : Proposed acquisition of the Company 1 Form 6 K	PU
09/10/24	Exscientia présentera de nouvelles données précliniques pour les inhibiteurs de la LSD1 et du MALT1 conçus par l'IA à l'ENA 2024	BU
09/10/24	Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024	BU
28/08/24	Exscientia participera à la 22e conférence annuelle de Morgan Stanley sur les soins médicaux dans le monde	BU
28/08/24	Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference	BU
15/08/24	Exscientia Business Update for Second Quarter and First Half 2024	BU
08/08/24	Exscientia : TRANSACTION AGREEMENT EXSCIENTIA PLC RECURSION PHARMACEUTICALS, INC Form 6 K	PU
18/07/24	Exscientia acquiert les droits complets d’un inhibiteur potentiel de CDK7, le meilleur de sa catégorie, avant la publication des données de dose croissante de phase 1	BU
18/07/24	Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout	BU
10/07/24	Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery	BU
25/06/24	EXAI LAWSUIT ALERT: The Gross Law Firm Notifies Exscientia plc Investors of a Class Action Lawsuit and Upcoming Deadline	PR
21/06/24	Exscientia plc Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAI	PR
20/06/24	Exscientia plc Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights - EXAI	PR
18/06/24	Lost Money on Exscientia plc(EXAI)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky	PR
17/06/24	Shareholders that lost money on Exscientia plc(EXAI) Urged to Join Class Action - Contact The Gross Law Firm to Learn More	PR
14/06/24	Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Exscientia plc(EXAI) Shareholders	PR
10/06/24	June 25, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against EXAI	PR
06/06/24	Exscientia nomme de nouveaux dirigeants pour accentuer l'impact des technologies intégrées et recentrer l'expertise en développement clinique sur l'oncologie	BU
06/06/24	Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology	BU